Clearside Biomedical, Inc.- IR Site News Releases https://ir.clearsidebio.com/ Clearside Biomedical, Inc.- IR Site News Releases en Clearside Biomedical to Present at the JMP Securities Life Sciences Conference https://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-present-jmp-securities-life-sciences ALPHARETTA, Ga. , June 11, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that Thomas A. Tue, 11 Jun 2019 07:05:00 -0400 Clearside Biomedical, Inc.- IR Site News Releases 8501 Clearside Biomedical to Present at the UBS Global Healthcare Conference https://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-present-ubs-global-healthcare-conference ALPHARETTA, Ga. , May 15, 2019 (GLOBE NEWSWIRE) -- ­­ Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that Brion Raymond , Chief Commercial Officer, will Wed, 15 May 2019 07:05:00 -0400 Clearside Biomedical, Inc.- IR Site News Releases 8471 Clearside Biomedical Announces First Quarter 2019 Financial Results and Provides Corporate Update https://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-announces-first-quarter-2019-financial - Scientific Presentations Support Broad Applicability of Clearside Delivery Platform -  - XIPERE ™ under review for October 19, 2019 PDUFA Date - - Management to Host Webcast and Conference Call Today at 8:30 A.M. ET - ALPHARETTA, Ga. , May 08, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical , Wed, 08 May 2019 07:05:00 -0400 Clearside Biomedical, Inc.- IR Site News Releases 8446 Clearside Biomedical’s Suprachoroidal Space Injection Platform Featured at Multiple Ophthalmology and Gene Therapy Medical Meetings https://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedicals-suprachoroidal-space-injection-platform - SCS injection platform continues to be well-received by the medical community - - Suprachoroidal administration may offer targeted delivery of gene therapies without risks of vitrectomy and subretinal surgery - ALPHARETTA, Ga. , May 01, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical , Wed, 01 May 2019 07:05:00 -0400 Clearside Biomedical, Inc.- IR Site News Releases 8441 Clearside Biomedical to Report First Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, May 8, 2019 https://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-report-first-quarter-2019-financial-results ALPHARETTA, Ga. , April 25, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its first quarter 2019 financial results will be Thu, 25 Apr 2019 07:05:00 -0400 Clearside Biomedical, Inc.- IR Site News Releases 8411 Clearside Biomedical Announces Multiple Presentations on its Suprachoroidal Space® Injection Platform at Upcoming Medical Meetings https://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-announces-multiple-presentations-its Posters to be presented on gene therapy and visual acuity ALPHARETTA, Ga. , April 18, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced Thu, 18 Apr 2019 07:05:00 -0400 Clearside Biomedical, Inc.- IR Site News Releases 8396 Clearside Biomedical Appoints Dr. George Lasezkay as Interim CEO https://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-appoints-dr-george-lasezkay-interim-ceo ALPHARETTA, Ga. , April 08, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its Board of Directors has appointed seasoned Mon, 08 Apr 2019 07:05:00 -0400 Clearside Biomedical, Inc.- IR Site News Releases 8376 Clearside Biomedical to Present at the 18th Annual Needham Healthcare Conference https://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-present-18th-annual-needham-healthcare ALPHARETTA, Ga. , April 02, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that Daniel H. Tue, 02 Apr 2019 16:05:00 -0400 Clearside Biomedical, Inc.- IR Site News Releases 8366 Clearside Biomedical Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update https://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-announces-fourth-quarter-and-full-year-2018 - Novel Retinal Treatment Demonstrates Potential of Proprietary Therapeutic Platform - - XIPERE ™ NDA Accepted and On Track for October 19, 2019 PDUFA Date - - Management to Host Webcast and Conference Call Today at 5:00 PM ET - ALPHARETTA, Ga. , March 12, 2019 (GLOBE NEWSWIRE) -- Clearside Tue, 12 Mar 2019 16:05:00 -0400 Clearside Biomedical, Inc.- IR Site News Releases 8326 Clearside Biomedical to Present at the Cowen and Company 39th Annual Health Care Conference https://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-present-cowen-and-company-39th-annual ALPHARETTA, Ga. , March 04, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that Daniel H. Mon, 04 Mar 2019 07:05:00 -0500 Clearside Biomedical, Inc.- IR Site News Releases 8321